- North American Vaccine and Abbott Laboratories have agreed that the latter will market and distribute NAV's combination vaccines for the prevention of polio and Hemophilus influenzae type b in the USA. They will be marketed to private physicians and managed care organizations in the USA by Abbott, and to the Centers for Disease Control and Prevention by NAV. Abbott will invest a total of $42 million in NAV including an equity investment and milestone payments. Both companies will collaborate in the clinical development of the vaccines, with funding provided by Abbott.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze